Details for Patent: 5,767,097
✉ Email this page to a colleague
Summary for Patent: 5,767,097
Title: | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
Abstract: | Ribavirin is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, ribavirin is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. Thus, instead of administering ribavirin in its well-recognized role as an anti-viral agent, ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection. |
Inventor(s): | Tam; Robert C. (Costa Mesa, CA) |
Assignee: | ICN Pharmaceuticals, Inc. (Costa Mesa, CA) |
Application Number: | 08/590,449 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 5,767,097
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,767,097
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 016597 | ⤷ Try a Trial | |||
Austria | 216886 | ⤷ Try a Trial | |||
Austria | 271063 | ⤷ Try a Trial | |||
Australia | 1747897 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |